The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
1. There are no new drugs designed to raise HDL anywhere close to coming to market2. Niacin remains the best agent on the market (in terms of HDL raising and improved outcomes) and is undergoing some potential improvement to reduce annoying side effects3. There remains great debate as to what the biological...
The surrogate atherosclerosis end point studies with torcetrapib promise to give important, but likely complex clues regarding its paradoxical increase in CVD events and mortality. Some promising HDL-raising approaches still appear to be eluding pharmaceutical R&D.Niacin promises to be a big winner...
1. Pfizer Inc, the pharmaceutical giant, halted late-stage trials of the HDL increasing drug torcetrapib after investigators discovered that it increased heart problems and increased death rates in the treated population. 2. Niacin, a B vitamin that increases HDL (the good cholesterol) up to 35%, has...
With the demise of the clinical development of Torcetrapib we are forced to reevaluate our views of HDL raising.We have had good HDL-raising drugs for many years, but they have gone underutilized and underappreciated.Many cardiologists (often supposed by others to be lipid experts) have never or rarely...
Niacin is one of the best drugs to treat hyperlipidemia in our armamentarium. It raises HDL (good CHL), and lowers both LDL and triglycerides, while statins essentially only target LDL metabolism. It is also one of the worst in terms of side effects. While LDL (bad cholesterol) is the primary target,...
This article is important as it highlights the many benefits of the Niacin drugs. It describes how MK-0524 may significantly increase adherence as it reduces the side effect of flushing. This article describes preliminary trials with the new formulation clearly showing a reduction in the...
Prasugrel in early studies appears to show advantages over Clopidogrel (Plavix) that could make it the preferred adjunctive agent in the setting of percutaneous coronary interventions (stent placements) and acute coronary syndromes. Effective anti-platelet agents are critical to the overall success...
1. Clopidogrel represents the state-of-the-art in oral antiplatelet therapy for patients undergoing percutaneous coronary intervention, but it is associated with certain suboptimal characteristics -- relatively slow onset of action, long half life, and potential for suboptimal platelet inhibition...